Hunan Jiudian Pharmaceutical Co., Ltd. (SHE:300705)
15.28
+0.19 (1.26%)
Feb 3, 2026, 3:04 PM CST
SHE:300705 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,052 | 2,930 | 2,691 | 2,325 | 1,627 | 975.71 |
Other Revenue | 1.15 | 1.15 | 1.02 | 0.89 | 0.82 | 2.45 |
| 3,053 | 2,931 | 2,693 | 2,326 | 1,628 | 978.16 | |
Revenue Growth (YoY) | 3.65% | 8.85% | 15.75% | 42.92% | 66.40% | 5.85% |
Cost of Revenue | 806.75 | 790.88 | 621.79 | 522.52 | 365.47 | 253.29 |
Gross Profit | 2,246 | 2,140 | 2,071 | 1,804 | 1,262 | 724.87 |
Selling, General & Admin | 1,461 | 1,331 | 1,405 | 1,285 | 878.31 | 547.49 |
Research & Development | 252.69 | 245.97 | 254.12 | 201.26 | 146.26 | 81.68 |
Other Operating Expenses | 39.83 | 25.15 | 28.47 | 25.87 | 21.04 | 14.26 |
Operating Expenses | 1,755 | 1,598 | 1,696 | 1,525 | 1,051 | 646.72 |
Operating Income | 491.32 | 541.62 | 375.12 | 278.84 | 211.22 | 78.16 |
Interest Expense | -13.55 | -18.63 | -11.06 | -18.42 | -16.01 | -5.25 |
Interest & Investment Income | 3.73 | 8.56 | 7.67 | 6.8 | 5.82 | 0.84 |
Currency Exchange Gain (Loss) | -0.26 | -0.26 | -0.42 | -0.27 | -0.14 | -0.34 |
Other Non Operating Income (Expenses) | -4.4 | -0.58 | -0.29 | -0.24 | -0.19 | -0.13 |
EBT Excluding Unusual Items | 476.84 | 530.71 | 371.02 | 266.71 | 200.7 | 73.28 |
Gain (Loss) on Sale of Investments | -0.34 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.05 | - | 0.03 | - | 0.02 | - |
Asset Writedown | -0.83 | -1.92 | -1.46 | -1.3 | -1.9 | -1.39 |
Other Unusual Items | 43.4 | 43.4 | 32.57 | 24.81 | 27.38 | 18.95 |
Pretax Income | 519.11 | 572.19 | 402.16 | 290.22 | 226.19 | 90.84 |
Income Tax Expense | 50.11 | 59.82 | 33.9 | 20.52 | 21.94 | 8.58 |
Earnings From Continuing Operations | 469 | 512.38 | 368.26 | 269.7 | 204.25 | 82.26 |
Minority Interest in Earnings | 0 | - | - | - | - | - |
Net Income | 469 | 512.38 | 368.26 | 269.7 | 204.25 | 82.26 |
Net Income to Common | 469 | 512.38 | 368.26 | 269.7 | 204.25 | 82.26 |
Net Income Growth | -7.68% | 39.13% | 36.55% | 32.05% | 148.29% | 49.38% |
Shares Outstanding (Basic) | 497 | 488 | 478 | 460 | 461 | 461 |
Shares Outstanding (Diluted) | 512 | 493 | 504 | 460 | 461 | 461 |
Shares Change (YoY) | 0.79% | -2.34% | 9.55% | -0.15% | 0.13% | -1.89% |
EPS (Basic) | 0.94 | 1.05 | 0.77 | 0.59 | 0.44 | 0.18 |
EPS (Diluted) | 0.92 | 1.04 | 0.73 | 0.59 | 0.44 | 0.18 |
EPS Growth | -8.40% | 42.47% | 24.64% | 32.24% | 147.98% | 52.26% |
Free Cash Flow | 125.17 | 348.5 | 4.37 | -144.39 | 64.94 | 71.64 |
Free Cash Flow Per Share | 0.24 | 0.71 | 0.01 | -0.31 | 0.14 | 0.16 |
Dividend Per Share | 0.313 | 0.313 | 0.229 | 0.169 | 0.133 | 0.022 |
Dividend Growth | 36.49% | 36.49% | 36.00% | 26.67% | 507.76% | 19.02% |
Gross Margin | 73.57% | 73.01% | 76.91% | 77.54% | 77.55% | 74.11% |
Operating Margin | 16.09% | 18.48% | 13.93% | 11.99% | 12.98% | 7.99% |
Profit Margin | 15.36% | 17.48% | 13.68% | 11.59% | 12.55% | 8.41% |
Free Cash Flow Margin | 4.10% | 11.89% | 0.16% | -6.21% | 3.99% | 7.32% |
EBITDA | 599.25 | 633.88 | 446.5 | 338.49 | 264.8 | 126.39 |
EBITDA Margin | 19.63% | 21.63% | 16.58% | 14.55% | 16.27% | 12.92% |
D&A For EBITDA | 107.92 | 92.26 | 71.37 | 59.64 | 53.58 | 48.24 |
EBIT | 491.32 | 541.62 | 375.12 | 278.84 | 211.22 | 78.16 |
EBIT Margin | 16.09% | 18.48% | 13.93% | 11.99% | 12.98% | 7.99% |
Effective Tax Rate | 9.65% | 10.45% | 8.43% | 7.07% | 9.70% | 9.45% |
Revenue as Reported | 3,053 | 2,931 | 2,693 | 2,326 | 1,628 | 978.16 |
Advertising Expenses | - | 79.64 | 73.01 | 77.41 | 28.51 | 1.8 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.